Last reviewed · How we verify
Fenway Community Health — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| TRUVADA + Raltegravir | TRUVADA + Raltegravir | marketed | Antiretroviral combination therapy (NRTI + INSTI) | HIV reverse transcriptase and HIV integrase | Infectious Disease / Virology |
Therapeutic area mix
- Infectious Disease / Virology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 shared drug class
- ViiV Healthcare · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Fenway Community Health:
- Fenway Community Health pipeline updates — RSS
- Fenway Community Health pipeline updates — Atom
- Fenway Community Health pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Fenway Community Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fenway-community-health. Accessed 2026-05-18.